UNSPSC 51391808: Gepefrine tartrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y64EJ7HA03, chemically known as phenol, 3-(2-aminopropyl)-, (s)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as gepefrine tartrate, which bears US NIH Compound Identifier 6454022. European Medicines Agency schedules gepefrine tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07896MIG.

Most nations, for tariff purposes, schedule gepefrine tartrate under HS 29222900. SMILES: C[C@@H](CC1CCCC(C1)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51391808 Gepefrine tartrate is a Commodity code that describes pharmaceutical active ingredients used in medications, though recent state and local solicitations tagged under this code show minimal activity directly aligned with the product. State and local governments solicit under this code sporadically and for narrow, specialized purposes. The two recent opportunities on record—one from Seminole County, Florida, and one from the Texas Health and Human Services Commission—show procurement of naloxone and pharmacy benefit program management rather than gepefrine tartrate specifically, indicating a mismatch between the code's nominal scope and actual buying patterns in state and local markets. Issuing bodies employing this code include county health departments and state HHS agencies, but the volume and frequency of solicitations remain limited.

Geographic activity centers on Florida and Texas based on recent postings. Seminole County, Florida issued an IFB in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI in April 2026 regarding direct-to-manufacturer prescription programs and vendor capabilities for pharmacy benefit management, representing exploratory procurement rather than a formal competitive solicitation. The limited recent activity and the disconnect between the code's pharmaceutical ingredient designation and the actual health-related products and services being solicited suggest this code sees minimal relevant state and local procurement demand.